Stockreport

Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon [Seeking Alpha]

Corvus Pharmaceuticals, Inc.  (CRVS) 
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corvuspharma.com
PDF 75% of patients on 200 mg soquelitinib BID achieved EASI 75, with benefits persisting one month post-treatment. Longer treatment duration improved outcomes, including [Read more]